The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-[1-(2-chlorobenzyl)-3-piperidyl]-N-(5-isoquinolyl)amine ID: ALA224508
Cas Number: 675133-18-3
PubChem CID: 10020867
Max Phase: Preclinical
Molecular Formula: C21H22ClN3
Molecular Weight: 351.88
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: Clc1ccccc1CN1CCCC(Nc2cccc3cnccc23)C1
Standard InChI: InChI=1S/C21H22ClN3/c22-20-8-2-1-5-17(20)14-25-12-4-7-18(15-25)24-21-9-3-6-16-13-23-11-10-19(16)21/h1-3,5-6,8-11,13,18,24H,4,7,12,14-15H2
Standard InChI Key: IYIMBHGTGWSTKM-UHFFFAOYSA-N
Molfile:
RDKit 2D
25 28 0 0 0 0 0 0 0 0999 V2000
4.5052 -17.5830 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.2205 -17.9962 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.9375 -17.5825 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.9347 -16.7513 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.5063 -16.7549 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.2176 -16.3431 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.2156 -15.5229 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.5030 -15.1137 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.7909 -15.5306 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.7965 -16.3494 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.6478 -16.3351 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.3647 -16.7446 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.3660 -17.5688 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.0789 -17.9783 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7945 -17.5655 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7925 -16.7390 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.0751 -16.3251 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.5070 -16.3252 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.2226 -16.7371 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.2189 -17.5608 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.9337 -17.9727 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.6491 -17.5588 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.6453 -16.7289 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.9301 -16.3209 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.9246 -15.4952 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
12 11 1 0
12 13 1 0
5 6 1 0
2 3 2 0
6 7 1 0
7 8 2 0
12 17 1 0
13 14 1 0
14 15 1 0
15 16 1 0
16 17 1 0
3 4 1 0
16 18 1 0
8 9 1 0
18 19 1 0
4 6 2 0
19 20 2 0
9 10 2 0
20 21 1 0
10 5 1 0
21 22 2 0
1 2 1 0
22 23 1 0
4 11 1 0
23 24 2 0
24 19 1 0
5 1 2 0
24 25 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 351.88Molecular Weight (Monoisotopic): 351.1502AlogP: 4.96#Rotatable Bonds: 4Polar Surface Area: 28.16Molecular Species: NEUTRALHBA: 3HBD: 1#RO5 Violations: ┄HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 8.10CX LogP: 4.03CX LogD: 3.25Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.72Np Likeness Score: -1.75
References 1. Iwakubo M, Takami A, Okada Y, Kawata T, Tagami Y, Sato M, Sugiyama T, Fukushima K, Taya S, Amano M, Kaibuchi K, Iijima H.. (2007) Design and synthesis of rho kinase inhibitors (III)., 15 (2): [PMID:17084087 ] [10.1016/j.bmc.2006.10.028 ] 2. Qin J, Lei B, Xi L, Liu H, Yao X.. (2010) Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis., 45 (7): [PMID:20347188 ] [10.1016/j.ejmech.2010.02.059 ]